

Original article

Comparative evaluation of the efficacy and tolerability of different doses of methotrexate in patients with psoriatic arthritis

Taylor S. Brown, Rosaria S. Erica

ABSTRACT

The comparative evaluation of the efficacy and tolerability of different doses of methotrexate in patients with psoriatic arthritis (PsA) is the focus of this study. Methotrexate is a disease-modifying antirheumatic drug commonly used in the treatment of PsA, but the optimal dosage remains uncertain. This original research article aims to compare the efficacy and tolerability of varying doses of methotrexate in PsA patients. A randomized controlled trial was conducted involving PsA patients who were assigned to different dosage groups of methotrexate. Efficacy outcomes, such as disease activity scores, joint assessments, and skin involvement, were measured at regular intervals. Tolerability was assessed by monitoring adverse events, laboratory parameters, and patient-reported outcomes. The study findings revealed that different doses of methotrexate had varying efficacy and tolerability profiles in PsA patients. Higher doses were associated with greater reductions in disease activity and improved joint and skin outcomes. However, these higher doses were also associated with increased incidence of adverse events and laboratory abnormalities. Lower doses showed moderate efficacy but had better tolerability profiles. This original article highlights the importance of individualized dosing in methotrexate treatment for PsA patients. While higher doses may provide greater efficacy, they may be accompanied by increased tolerability concerns. Lower doses may offer a balance between efficacy and tolerability. Clinicians should consider patient-specific factors, such as disease severity, comorbidities, and tolerability, when determining the optimal dosage of methotrexate for PsA management.

Keywords: *Methotrexate, psoriatic arthritis, efficacy, tolerability,*

Non-Open access article

To get the full text of this paper, please contact the editorial board or the support team at: editor@clinician.site, support@clinician.site